| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/31/2002 | CA2416751A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | CA2416750A1 Compounds having mif antagonist activity |
| 01/31/2002 | CA2416681A1 Composition for treatment of ocular hypertension and glaucoma |
| 01/31/2002 | CA2416676A1 Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof |
| 01/31/2002 | CA2416664A1 Zinc finger domain recognition code and uses thereof |
| 01/31/2002 | CA2416657A1 Fh-binding protein of streptococcus pneumoniae |
| 01/31/2002 | CA2416608A1 Pharmaceutically active compound |
| 01/31/2002 | CA2416537A1 Calcilytic compounds |
| 01/31/2002 | CA2416447A1 Novel compounds and their use as glycine transport inhibitors |
| 01/31/2002 | CA2415900A1 Uses for nad synthetase inhibitors |
| 01/31/2002 | CA2415742A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | CA2415740A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | CA2415606A1 Capsaicin receptor ligands |
| 01/31/2002 | CA2415585A1 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | CA2415368A1 Synthesis and antiviral evaluation of nucleic acid based (nab) libraries |
| 01/31/2002 | CA2415362A1 Method for treating fibrotic diseases or other indications |
| 01/31/2002 | CA2415196A1 Cyclic substituted aminomethyl compounds and medicaments comprising these compounds |
| 01/31/2002 | CA2415131A1 Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2415054A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | CA2415046A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | CA2412392A1 Use of estramustine phosphate in the treatment of bone metastasis |
| 01/31/2002 | CA2412376A1 Pharmaceutical suspension compositions lacking a polymeric suspending agent |
| 01/31/2002 | CA2412373A1 Method for enhancing bone mineral density gain |
| 01/31/2002 | CA2411195A1 Aryl sulfonamides as serotonin antagonist for the treatment of obesity |
| 01/31/2002 | CA2411192A1 Combination of serotonin agonist (5ht2) and antagonist (5ht6)as a pharmaceutical formulation |
| 01/31/2002 | CA2410766A1 Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2410683A1 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 01/31/2002 | CA2410682A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2410562A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/31/2002 | CA2354236A1 Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| 01/30/2002 | EP1176208A1 Koji molds and use thereof for preparing cholesterol-lowering products |
| 01/30/2002 | EP1176149A1 Novel gymnemic acid derivatives, process for the preparation thereof and use thereof as medicine |
| 01/30/2002 | EP1176148A1 Benzothiadiazine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 01/30/2002 | EP1176147A1 Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof |
| 01/30/2002 | EP1176146A1 Carbamoyl tetrahydropyridine derivatives |
| 01/30/2002 | EP1176145A1 Novel guanidino derivatives as inhibitors of cell adhesion |
| 01/30/2002 | EP1176144A1 N-triazolylmethyl-piperazine derivatives as neurokinine receptor-antagonists |
| 01/30/2002 | EP1176140A1 Amide compounds and medicinal use thereof |
| 01/30/2002 | EP1176139A1 Medicinal compositions with 2.2.1] and 3.1.1] bicycloskeleton antagonistic to both of pgd 2?/txa 2? receptors |
| 01/30/2002 | EP1176134A1 Ligands of nuclear receptors ppar's |
| 01/30/2002 | EP1175915A1 A method for preparing resinates |
| 01/30/2002 | EP1175914A2 A resinate composition |
| 01/30/2002 | EP1175913A1 Intramuscular pharmaceutical composition comprising dexibuprofen and uses thereof |
| 01/30/2002 | EP1175912A1 Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| 01/30/2002 | EP1175910A2 Methods and compounds for prevention of graft rejection |
| 01/30/2002 | EP1175909A2 Therapeutic methods and compositions based on serrate proteins and nucleic acids |
| 01/30/2002 | EP1175908A1 Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
| 01/30/2002 | EP1175907A1 Remedies |
| 01/30/2002 | EP1175906A1 Blood flow improvers and thrombosis preventives or remedies comprising glucosamine |
| 01/30/2002 | EP1175905A1 Nutritional Composition |
| 01/30/2002 | EP1175904A2 Method for inhibiting bone resorption |
| 01/30/2002 | EP1175903A2 Method for inhibiting bone resorption |
| 01/30/2002 | EP1175902A1 Use of CS-866 (olmesartan) in the manufacture of a medicament for treating arteriosclerosis |
| 01/30/2002 | EP1175901A1 Peroxisome activator-responsive receptor agonists |
| 01/30/2002 | EP1175900A2 Use of growth hormone secretagogues for improvement of fucnctional health status |
| 01/30/2002 | EP1175897A2 Cosmetic or dermatologic formulation to treat and cool the skin after a sun bath |
| 01/30/2002 | EP1175892A1 Use of EP-3 prostaglandins receptor antagonists as cosmetic agent for reducing or stopping hairloss |
| 01/30/2002 | EP1175890A1 Use of E2 (EP-3) prostaglandins receptor agonists for reducing or stopping hairloss in cosmetic compositions |
| 01/30/2002 | EP1175888A2 Topical compositions comprising glycosylated hydroxystilbenes and their uses |
| 01/30/2002 | EP1175616A1 Methods for the diagnosis and treatment of metastatic prostate tumors |
| 01/30/2002 | EP1175513A1 MinK-RELATED GENES, FORMATION OF POTASSIUM CHANNELS AND ASSOCIATION WITH CARDIAC ARRHYTHMIA |
| 01/30/2002 | EP1175503A1 49 human secreted proteins |
| 01/30/2002 | EP1175502A1 Halo- or hydroxy-substituted nocathiacin antibiotics |
| 01/30/2002 | EP1175498A2 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
| 01/30/2002 | EP1175497A2 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| 01/30/2002 | EP1175489A1 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same |
| 01/30/2002 | EP1175487A2 Pancreatic progenitor cells, methods and uses related thereto |
| 01/30/2002 | EP1175438A1 62 human secreted proteins |
| 01/30/2002 | EP1175434A2 Eplerenone crystalline form |
| 01/30/2002 | EP1175433A1 Androgen glycosides and androgenic activity thereof |
| 01/30/2002 | EP1175432A1 Processes for the synthesis of oligomers using phusphoramidite compositions |
| 01/30/2002 | EP1175429A1 Halo derivatives of 9-deoxo-9a-aza-9a-homerythromycin a |
| 01/30/2002 | EP1175428A1 3-deoxy-desmycosin derivatives and process for their preparation |
| 01/30/2002 | EP1175421A1 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
| 01/30/2002 | EP1175420A2 Process for preparing n6-substituted deaza-adenosine derivatives |
| 01/30/2002 | EP1175418A2 Thiazolidinedione derivative and its use as antidiabetic |
| 01/30/2002 | EP1175417A1 Substituted benzolactam compounds |
| 01/30/2002 | EP1175416A1 Heteroaryl diazacycloalkanes, their preparation and use |
| 01/30/2002 | EP1175413A1 2,1-benzisothiazoline 2,2-dioxides |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175411A1 Cyclothiocarbamate derivatives as progesterone receptor modulators |
| 01/30/2002 | EP1175409A1 Pyrimidinones derivatives for the treatment of atherosclerosis |
| 01/30/2002 | EP1175408A1 Pyrimidinone compounds |
| 01/30/2002 | EP1175406A1 Imidazoline derivatives as alpha-1a adrenoceptor ligands |
| 01/30/2002 | EP1175405A1 LACTAM INHIBITORS OF FXa AND METHOD |
| 01/30/2002 | EP1175404A1 Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| 01/30/2002 | EP1175403A1 6,7-disubstituted-5,8-quinolinedione derivatives as an antifungal agent |
| 01/30/2002 | EP1175402A1 Piperidine derivatives useful as ccr5 antagonists |
| 01/30/2002 | EP1175401A1 Piperazine derivatives useful as ccr5 antagonists |
| 01/30/2002 | EP1175400A1 Renin inhibitors |
| 01/30/2002 | EP1175398A1 Indoline derivatives as progesterone antagonists |
| 01/30/2002 | EP1175397A1 3,3-substituted indoline derivatives |
| 01/30/2002 | EP1175383A1 Glucocorticoid receptor modulators |
| 01/30/2002 | EP1175246A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
| 01/30/2002 | EP1175224A2 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 01/30/2002 | EP1175223A2 Methods and compositions for modulating an immune response |
| 01/30/2002 | EP1175220A2 Nanoparticulate eplerenone compositions |
| 01/30/2002 | EP1175219A1 Treatment of bone cancer |
| 01/30/2002 | EP1175218A1 Ocular therapy in keratoconjuctivitis sicca using topically applied androgens or tgf-beta |